LTRN earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -1.96. Updated 2026-07-23.
Lantern Pharma (LTRN) Research Hub
Lantern Pharma (LTRN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.71 USD (-3.39%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.96, market cap 0.04B. This hub links to the full technical, earnings and options research available for LTRN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.71 USD (-3.39%) |
| 52-week range | 1.7 USD – 4.2 USD |
| Trend regime | Range |
| 14-day RSI | 3.3 (Oversold) |
| Trailing P/E | -1.96 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for LTRN
Covered Call on LTRN: how it works, illustrative setup around the real 1.71 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LTRN: how it works, illustrative setup around the real 1.71 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LTRN: how it works, illustrative setup around the real 1.71 USD price, max profit/loss, breakeven and when to use it. Educational.
LTRN technical analysis: range, last 1.71 USD, RSI 3.3, 52w range 1.7 USD–4.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LTRN in?
Lantern Pharma (LTRN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LTRN in an uptrend or downtrend?
As of 2026-09-11, LTRN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LTRN's trailing P/E ratio?
LTRN's trailing P/E is -1.96, with a market cap of 0.04B. See the earnings research page for full valuation detail.
When does LTRN next report earnings?
LTRN is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.38 USD.